Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator

被引:12
|
作者
Daimee, Usama A. [1 ]
Vermilye, Katherine [1 ]
Moss, Arthur J. [1 ]
Goldenberg, Ilan [1 ]
Klein, Helmut U. [1 ]
McNitt, Scott [1 ]
Zareba, Wojciech [1 ]
Kutyifa, Valentina [1 ]
机构
[1] Univ Rochester, Med Ctr, Div Cardiol, Heart Res Follow Up Program, 265 Crittenden Blvd,Box 653, Rochester, NY 14642 USA
关键词
Compliance; Implantable cardioverter-defibrillator; Older patients; Ventricular tachyarrhythmias; Wearable cardioverter-defibrillator; ACUTELY TERMINATING EPISODES; HIGH-RISK; VENTRICULAR-FIBRILLATION; ATRIAL-FIBRILLATION; CLINICAL-EFFICACY; DYSFUNCTION; INFARCTION; THERAPY; SHOCKS;
D O I
10.1016/j.hrthm.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Use of the wearable cardioverter-defibrillator (WCD) in older patients has not been described previously. OBJECTIVE The purpose of this study was to assess WCD wear time, risk of arrhythmic events during WCD use, and implantable cardioverter-defibrillator (ICD) implantation rates after the end of WCD use in patients with age >= 65 years vs <65 years. METHODS We stratified 1732 patients with ischemic and nonischemic cardiomyopathy from the Prospective Registry of Patients Using the Wearable Defibrillator Registry into 2 subgroups by age: those with age >= 65 years and those with age <65 years. Wear time, arrhythmic events, and end-of-use decisions, specifically ICD implantation or improvement in ejection fraction, were evaluated for each age group. RESULTS There were 722 patients with age >= 65 years (41.7%) and 1010 patients with age <65 years (58.3%). Daily WCD wear time was longer in the older population (median 22.8 h/d (IQR 21.5 23.2) vs 22.3 h/d (IQR 19.5- 23.0); P <.001). Patients with age >= 65 years experienced higher event rates, per 100 patient-years, for any sustained ventricular tachycardia/ventricular fibrillation (31.95 vs 9.82; P =.027) and ventricular tachycardia/ventricular fibrillation treated with WCD shock (6.92 vs 2.37; P =.034), particularly with ischemic cardiomyopathy. Younger patients experienced a trend toward a higher event rate for atrial arrhythmias with nonischemic cardiomyopathy (150.07 vs 74.86; P =.055). At the end of WCD use, ICD implantation was more frequent in older patients (41.8% vs 36.5%; P =.034). CONCLUSION Older patients had good compliance with the WCD, presented with more frequent ventricular arrhythmias, and were more likely to receive an ICD at the end of WCD use. The WCD may play a role in risk stratification of the older population.
引用
收藏
页码:1379 / 1386
页数:8
相关论文
共 50 条
  • [21] The wearable cardioverter-defibrillator is needed for most high-risk patients
    Lee, Byron K.
    HEART RHYTHM O2, 2020, 1 (03): : 227 - 229
  • [22] The wearable cardioverter-defibrillator is not needed for most high-risk patients
    Bhatt, Advay G.
    Mittal, Suneet
    HEART RHYTHM O2, 2020, 1 (03): : 230 - 233
  • [23] The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients
    Julia W. Erath
    Mate Vamos
    Abdul Sami Sirat
    Stefan H. Hohnloser
    Clinical Research in Cardiology, 2017, 106 : 300 - 306
  • [24] Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry
    Christian Veltmann
    Stefan Winter
    David Duncker
    Carsten G. Jungbauer
    Nadine K. Wäßnig
    J. Christoph Geller
    Julia W. Erath
    Olaf Goeing
    Christian Perings
    Michael Ulbrich
    Mattias Roser
    Daniela Husser
    Laura S. Gansera
    Korkut Soezener
    Frank Michael Malur
    Michael Block
    Thomas Fetsch
    Valentina Kutyifa
    Helmut U. Klein
    Clinical Research in Cardiology, 2021, 110 : 102 - 113
  • [25] Wearable cardioverter-defibrillator: friend or foe in suspected myocarditis?
    Blaschke, Florian
    Lacour, Philipp
    Dang, Phi Long
    Parwani, Abdul Shokor
    Hohendanner, Felix
    Walter, Thula
    Klingel, Karin
    Kuehl, Uwe
    Heinzel, Frank R.
    Sherif, Mohammad
    Boldt, Leif-Hendrik
    Pieske, Burkert
    Tschoepe, Carsten
    ESC HEART FAILURE, 2021, 8 (04): : 2591 - 2596
  • [26] The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital
    Anil-Martin Sinha
    Jens Bense
    Wolfgang Hohenforst-Schmidt
    Journal of Interventional Cardiac Electrophysiology, 2021, 62 : 401 - 407
  • [27] Patient-reported outcomes using a wearable cardioverter-defibrillator: results from a systematic review
    Aidelsburger, Pamela
    Seyed-Ghaemi, Janine
    Bonderman, Diana
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [28] Safety of the Wearable Cardioverter Defibrillator (WCD) in Patients with Implanted Pacemakers
    Schmitt, Joern
    Abaci, Guezine
    Johnson, Victoria
    Erkapic, Damir
    Gemein, Christopher
    Chasan, Ritvan
    Weipert, Kay
    Hamm, Christian W.
    Klein, Helmut U.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2017, 40 (03): : 271 - 277
  • [29] Current status of wearable cardioverter-defibrillator use in Japan
    Tonegawa-Kuji, Reina
    Nishida, Taku
    Sumita, Yoko
    Miyamoto, Yoshihiro
    Kanaoka, Koshiro
    JOURNAL OF ARRHYTHMIA, 2024, 40 (04) : 998 - 1000
  • [30] Sex differences and adherence of patients treated with wearable cardioverter-defibrillator: Insights from an international multicenter register
    Abumayyaleh, Mohammad
    Dreher, Tobias C.
    Rosenkaimer, Stephanie
    Roeger, Susanne
    Erath, Julia W.
    Klein, Norbert
    Kovacs, Boldizsar
    Duru, Firat
    Saguner, Ardan M.
    El-Battrawy, Ibrahim
    Akin, Ibrahim
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2022, 33 (11) : 2243 - 2249